









Markets
/
Stocks
/
nasdaq-mygn
/

Myriad Genetics Inc

MYGN

7.680USD

+0.280+3.78%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

715.01MMarket Cap

LossP/E TTM



Myriad Genetics Inc

7.680

+0.280+3.78%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

68 / 207

Overall Ranking

180 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Hold

Current Rating

7.167

Target Price

-3.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 23.47% year-on-year.

Overvalued

The company’s latest PE is -1.78, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 100.80M shares, decreasing 1.80% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.15M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.07.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 7.13, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 213.10M, representing a year-over-year increase of 0.76%, while its net profit experienced a year-over-year increase of 800.54%.

Score

Industry at a Glance

Previous score

7.13

Change



Financials

7.11

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.49

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.35

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -1.72, which is 285.46% below the recent high of -6.63 and -651.01% above the recent low of -12.91.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 5.73, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Myriad Genetics Inc is 6.00, with a high of 18.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

5.73

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Hold

Current Rating

7.167

Target Price

-3.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Myriad Genetics Inc

MYGN

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 8.67, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 8.39 and the support level at 5.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.67

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.090

Buy

RSI(14)

69.105

Neutral

STOCH(KDJ)(9,3,3)

82.296

Neutral

ATR(14)

0.441

High Vlolatility

CCI(14)

114.128

Buy

Williams %R

7.547

Overbought

TRIX(12,20)

1.317

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

7.426

Buy

MA10

7.220

Buy

MA20

6.738

Buy

MA50

5.714

Buy

MA100

5.423

Buy

MA200

8.631

Sell

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 108.34%, representing a quarter-over-quarter increase of 0.71%. The largest institutional shareholder is The Vanguard, holding a total of 9.15M shares, representing 9.83% of shares outstanding, with 15.07% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

13.85M

-3.29%

The Vanguard Group, Inc.

Star Investors

10.62M

+0.44%

Millennium Management LLC

4.07M

-6.34%

State Street Global Advisors (US)

5.27M

-4.65%

Glenview Capital Management, LLC

Star Investors

3.90M

-6.20%

D. E. Shaw & Co., L.P.

2.52M

+38.62%

Morgan Stanley & Co. LLC

1.41M

+44.81%

Geode Capital Management, L.L.C.

2.23M

+4.10%

Dimensional Fund Advisors, L.P.

2.21M

-2.60%

Qube Research & Technologies Ltd

1.42M

+41.62%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 2.99, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.98. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.